DermTech (MEX:DMTK) Debt-to-Equity : 1.34 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is DermTech Debt-to-Equity?

DermTech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN53.3 Mil. DermTech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN837.4 Mil. DermTech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was MXN663.8 Mil. DermTech's debt to equity for the quarter that ended in Mar. 2024 was 1.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for DermTech's Debt-to-Equity or its related term are showing as below:

MEX:DMTK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.14 Max: 1.34
Current: 1.34

During the past 8 years, the highest Debt-to-Equity Ratio of DermTech was 1.34. The lowest was 0.00. And the median was 0.14.

MEX:DMTK's Debt-to-Equity is ranked worse than
90.72% of 194 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs MEX:DMTK: 1.34

DermTech Debt-to-Equity Historical Data

The historical data trend for DermTech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech Debt-to-Equity Chart

DermTech Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.03

0.42

0.95

DermTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.52	0.63	0.76	0.95	1.34

Competitive Comparison of DermTech's Debt-to-Equity

For the Diagnostics & Research subindustry, DermTech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DermTech's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, DermTech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where DermTech's Debt-to-Equity falls into.

DermTech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

DermTech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(52.383	+	870.915)	/	970.503
	=	0.95

DermTech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(53.291	+	837.414)	/	663.751
	=	1.34

DermTech (MEX:DMTK) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

DermTech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of DermTech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

DermTech (MEX:DMTK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (MEX:DMTK) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DMTK:USA

Address

11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037

Website

https://www.dermtech.com

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.